Form 4 for LONA LeonaBio, Inc.
Accepted 2023-01-23 00:00:00 ET · period of report 2023-01-19 · accession 0001209191-23-004468 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-01-23 | 2022-11-18 | LONA | CHURCH KEVIN | Executive VP, Research | A - Grant | $2.74 | +657 | 62.1K | +1% | +$1,800 |
| D | 2023-01-23 | 2023-01-19 | LONA | CHURCH KEVIN | Executive VP, Research | A - Grant | $0.00 | +150.0K | 150.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-11-18 | A | A | 657 | $2.74 | 62,052 | D | — | — | (F1) The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP Purchase Period (as defined in the ESPP) of May 18, 2022 through November 18, 2022. This transaction is also exempt under Rule 16b-3(c). (F2) The Purchase Period ended November 18, 2022 and is the sole Purchase Period in the Offering Period (as defined in the ESPP) that began May 18, 2022. (F3) In accordance with the ESPP, these shares were purchased based on 85% of the closing price on November 18, 2022. |
| 2 | Derivative | Stock Option (Right to Buy) | 2023-01-19 | A | A | 150,000 | $0.00 | 150,000 | D | $3.37 · — to 2033-01-18 | 150,000 Common Stock | (F4) One thirty-sixth (1/36th) of the shares subject to the option will vest on February 19, 2023 and one thirty-sixth of the shares subject to the option will vest each month thereafter. |